USD 3.89 Billion
Migraine Drugs Market Size, Share, Growth Analysis, By Treatment Class (Acute/Abortive Treatment, Preventive/Prophylactic Treatment), By Therapeutic Class (Triptans, Acetylcholine Inhibitors/Neurotoxins), By Route of Administration (Oral, Injectables), By Region - Industry Forecast 2024-2031.
Report ID:
SQMIG35I2350 |
Region:
Global |
Published Date: November, 2024
Pages:
207
|Tables:
94
|Figures:
71
Migraine Drugs Market Insights
Global Migraine Drugs Market size was valued at USD 3.89 Billion in 2022 and is poised to grow from USD 4.50 Billion in 2023 to USD 17.25 Billion by 2031, growing at a CAGR of 18.0% in the forecast period (2024-2031).
As the name suggests, migraine drugs are medicines that are mainly designed to alleviate or prevent migraine symptoms. The two major categories of these medications include acute medicines and preventive medicines, wherein acute medicines are used to cure the attacks that have lately begun, and preventive medicines lessen the frequency of severe attacks. The market is significantly driven by the growing awareness of effective preventive solutions, availability of improved diagnosis, and the launch of novel medications. Nonetheless, a few factors restraining the growth of the market include significantly priced novel treatments and possible side-effects that may create hesitation among physicians and patients for use. Yet, the market is expected to grow considerably in the forthcoming years owing to modernizations in drug development, inclination towards personalized medicine, and notable growth potential in the developing markets.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Prescription Drugs
Fastest Growth
Adult
Growth Rate
18.0%
Global Migraine Drugs Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Migraine Drugs Market Segmental Analysis
Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Treatment Class
Based on treatment class, the migraine drugs market is segmented as Acute/Abortive Treatment and Preventive/Prophylactic Treatment. The acute/abortive treatment segment held a significant share of the market in 2023 and is anticipated to lead over the forecast period owing to the immediate relief offered and mounting demand due to its well-establishment. Acute treatments are known to offer speedy relief from symptoms once the attack starts. This is the key reason the treatment is highly preferred by patients who seek immediate symptom management. A broader range of acute medicines like NSAIDs, triptans, and ergots provide multiple choices customized as per patients’ requirements. This is also contributing to segmental growth.
The preventive/prophylactic treatment segment is anticipated to be the fastest-growing segment owing to less frequency of attacks and long-term efficiency. Preventive treatments significantly decrease the severity and frequency of migraines. This enhances the patient’s life quality and decreases the burden of the said condition. These treatments also offer prolonged advantages by addressing the key triggers and stabilizing the brain activities. This increases its prominence among patients with severe or frequent migraine attacks.
Analysis by Route of Administration
Based on route of administration, the market is segmented into oral, injectables, and others. The oncology segment dominated the market in the past years and is projected to lead in future as well owing to its faster relief and increased efficacy. Injectables, mainly novel biologics, such as CGRP inhibitors mostly offer effective and fast relief than oral medicines. Injectables can effectively ensure better effectiveness and absorption in preventive treatment. This route of administration also offers prolonged relief, lessening the need for extra doses and enhance patient compliance, impacting the segment’s growth.
On the other hand, the oral segment is projected to hold a significant market share in the coming years owing to its easy usage and convenience. Oral medicines can be easily consumed and need no special form of administration. This increased their convenience for patients than the injectables. Also, these medicines are available on a global scale, comprising triptans, NSAIDs, and several other preventive medicines. They cater to a broader range of consumers as per their preferences and needs. Furthermore, the segmental growth is impacted by its cost-efficiency than injectables, making them highly accessible and attractive option to patients and healthcare professionals.
Global Migraine Drugs Market Size By Treatment Class
To get detailed analysis on other segments, Request For Free Sample Report
Migraine Drugs Market Regional Insights
Region-wise, North America is the dominating region among others and is expected to lead over the forecast period owing to the increasing cases of migraines and higher awareness of drugs among patients and healthcare professionals. This results in elevated demand for efficient treatments. Regional growth is also impacted by the presence of well-developed healthcare infrastructure that facilitates better distribution of migraine medicines and better access to multiple treatments. Also, the existence of a greater number of pharma companies that drive availability and innovations is notably affecting the growth of the market. The key players operating in the region include AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim, Novartis International AG, and more.
Europe is the fastest-growing region in global migraine drugs market due to the growing cases of migraines and increased rate of diagnosis. Europe holds comparatively increased number of migraine patients and improved diagnostic treatments. This results in higher demand for effective and reliable treatments. Another reason for the regional growth is attributed to well-funded and superior healthcare systems in several countries to aid innovative therapies and migraine treatments. The region also holds a supportive regulatory environment for the approval of novel migraine treatments.
Global Migraine Drugs Market Size By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Migraine Drugs Market Dynamics
Drivers
Improvements in Drug Development
- The introduction of novel drug categories like CGRP gepants and inhibitors represents major progress. These novel treatments provide deep targeted mechanisms and have proved their efficiency in lessening the severity and frequency of migraines. This is majorly propelling more improvements, thus market growth. Also, constant research in migraine pathophysiology is resulting in the development of modernized therapies. Improvements in interpreting the genetic and molecular basis of migraines are fueling the development of personalized treatments.
Significant Growth of Personalized Medicine
- The inclination towards personalized medication comprises tailoring treatments depending on the patient’s profiles like lifestyle and genetic factors. This approach enhances the efficiency of the treatment patient compliance. Also, improvements in biomarker identification and genetic research allow the growth of targeted therapies, which may result in enhanced migraine management, thus impacting the market growth.
Restraints
Side-Effects and Limited Efficacy
- Despite improvements, not every drug or treatment responds well to patients. The effectiveness of any drug may differ from patient to patient, thus leading to dissatisfaction and less adoption. They may shift to other alternative therapies. Novel medicines may also offer a few side effects, which may limit the quality of life of patients. This could result in the discontinuation of the medicine or demanding additional medicines to alleviate adverse effects.
Lack of Education and Awareness
- The awareness of the availability of novel migraine treatments is still low in unexplored areas. patients may not be completely aware of the advantages of the progressing therapies. Healthcare providers may also not be updated with the availability of modern treatment options. This may limit their experience with novel drugs, impacting the adoption of these therapies.
Request Free Customization of this report to help us to meet your business objectives.
Migraine Drugs Market Competitive Landscape
The global migraine drugs market is a highly competitive global market driven by many international competitors. Prominent corporations with cutting-edge AI and ML technology are Google, IBM, Microsoft, and NVIDIA. To support a wide range of applications across industries, these industry experts concentrate on creating cutting-edge algorithms, scalable platforms, and reliable infrastructure. Rapid advances in technology, strategic alliances, and large expenditures on research and development define the competitive environment.
Top Player’s Company Profiles
- Pfizer
- GlaxoSmithKline
- Allergan
- Amgen
- Eli Lilly
- Teva Pharma
- Biohaven Pharma
- Johnson & Johnson
- Valeant Pharma
- AbbVie Inc.
- Eli Lilly and Company
- Novartis International AG
- Biohaven Pharmaceuticals
- Boehringer Ingelheim
- Zynerba Pharmaceuticals
- Teva Pharmaceutical
- Hoffmann-La Roche Ltd
- Amgen
- AstraZeneca
Recent Developments
- In February 2022, Biohaven Pharmaceuticals and Pfizer Inc. announced that the CHMP and EMA approved their (CGRP) calcitonin gene-related peptide receptor antagonist, named rimegepant for both acute treatment patients and preventive treatments.
- In March 2023, The U.S. FDA approved (PFE.N) by Pfizer Incorporation. This novel nasal spray offers patients access to a reliable and immediate relief option for migraines and headaches.
- In June 2024, GlaxoSmithKline announced that it received approval from the U.S. FDA for its Arexvy (RSV) Respiratory Syncytial Virus Vaccine, named Adjuvanted for avoiding RSV LRTD (lower respiratory tract disease) in adults of 50-60 years of age.
Migraine Drugs Key Market Trends
- Development of CGRP Inhibitors: The CGRP (calcitonin gene-related peptide) inhibitors have gained popularity in less time for the treatment of migraine. Drugs, such as Aimovig (erenumab), Emgality (galcanezumab), and Ajovy (fremanezumab) have proven their efficacy in decreasing migraine frequency and severity. They have progressed as highly preferred options for preventive migraine treatment. These medicines offer quarterly or monthly dosing, offering sustained efficiency for chronic sufferers of chronic migraine.
- Improvements in Drug Delivery Systems: Novel injectables treatments are offering prolonged relief with a smaller number of doses like quarterly or monthly injections. This trend comprises drugs, such as Emgality and Aimovig that are specifically designed for prolonged management of migraine. Growth is also seen in alternative drug delivery systems like transdermal patches and nasal sprays, that offer wider choices for patients with unique needs.
Migraine Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the migraine drugs market is witnessing considerable growth due to the growing awareness and diagnosis, growing healthcare expenditure, and the emergence of personalized medicine. The market is also propelled by the growing unmet medical needs, especially for neurological ailments. However, the market is restrained by approval and regulatory challenges, and healthcare system limitations. North America is anticipated to lead the market owing to the high healthcare spending, presence of leading market players, and improved healthcare infrastructure. Nonetheless, some opportunities for the growth of the migraine drugs market include technological improvements, policy support, and growing patient education in several unexplored regions.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 3.89 Billion |
| Market size value in 2031 | USD 17.25 Billion |
| Growth Rate | 18.0% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Migraine Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Migraine Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Migraine Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Migraine Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Migraine Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Migraine Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
